Clover Biopharmaceuticals, Ltd. (HKG:2197)

Market Cap	2.86B +909.9%
Revenue (ttm)	56.73M +79.2%
Net Income	-996.69M
EPS	-0.79
Shares Out	1.30B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,064,000
Average Volume	3,194,312
Open	2.210
Previous Close	2.230
Day's Range	2.180 - 2.230
52-Week Range	0.185 - 3.180
Beta	3.53
RSI	38.06
Earnings Date	Mar 27, 2026

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 243
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2197

Financial Performance

In 2024, Clover Biopharmaceuticals's revenue was 38.42 million, a decrease of -2.13% compared to the previous year's 39.26 million. Losses were -903.43 million, 552.1% more than in 2023.

Financial numbers in CNY